georgeclerk
- Oppenheimer upgraded Incyte (INCY) to outperform from market perform, saying that the company is poised for growth beyond Jakafi’s (ruxolitinib) loss of exclusivity in 2029.
- The firm has a $144 price target (~23% upside based on Oct. 29 close).
- Analyst